Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  octreotide acetate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-10 of 10 for your search:
Start Over
Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
Phase: Phase IV
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 541923, NCT02032784
Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: EudraCT 2006-004748-22, NCT01203306
IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BJT-NEC-001, NCT01480986
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRE12-158, NCT02101385
Trabectedin for Recurrent Grade II/III Meningioma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-1320, NCT02234050
Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Ist Nazionale Tumori Milano, NCT02294006
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Phase: Phase II
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 117314, NCT02294786
Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HS-12-455, NCT02299089
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-09, 2014-003694-42, RCAPHM14_0080, NCT02333565
Octreotide LAR as Maintenance Treatment for Patients With NEC
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Not specified
Sponsor: Other
Protocol IDs: BJT-NEC-002, NCT02409849
Start Over